Financial Performance - The company's operating revenue for Q1 2024 was RMB 161,591,937.51, representing a year-on-year increase of 4.30%[26] - The net profit attributable to shareholders of the listed company for Q1 2024 was a loss of RMB 118,958,055.48[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 122,773,183.58[26] - The basic and diluted earnings per share for Q1 2024 were both -0.29 RMB[26] - The weighted average return on net assets for Q1 2024 was -10.32%[26] - Total operating revenue for Q1 2024 was $161.59 million, an increase of 4.3% compared to $154.93 million in Q1 2023[41] - Net profit for Q1 2024 was a loss of $118.96 million, an improvement from a loss of $142.58 million in Q1 2023[42] - Basic and diluted earnings per share for Q1 2024 were both -0.29, compared to -0.34 in Q1 2023[44] - The company's net loss for the period was CNY -119,035,070.61, an improvement from CNY -143,294,729.60 in the previous period[55] - The company reported a net loss of CNY 118,895,169.25 for Q1 2024, an improvement from a net loss of CNY 140,205,070.68 in Q1 2023[82] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,352[17] - The largest shareholder, Guangzhou Qixi Group Co., Ltd., held 38.64% of the shares, totaling 159,990,270 shares[17] - Therabio International Limited, the second-largest shareholder, held 11.39% of the shares, totaling 47,177,729 shares[17] - The company has not reported any significant changes in the top 10 shareholders due to margin trading or securities lending[21] Cash Flow and Liquidity - The net cash flow from operating activities for Q1 2024 was a negative RMB 64,803,155.03[26] - Net cash flow from operating activities increased due to higher cash received from sales of goods and services[28] - Cash and cash equivalents increased to ¥341,977,265.74 from ¥163,986,759.82, reflecting improved liquidity[36] - Cash and cash equivalents at the end of Q1 2024 totaled $295.74 million, down from $357.78 million at the end of Q1 2023[48] - The net cash flow from financing activities in Q1 2024 was $74.15 million, a decrease from $248.69 million in Q1 2023[48] - Cash inflow from operating activities for Q1 2024 was $220,047,817.51, an increase of 18.3% compared to $186,026,836.36 in Q1 2023[85] - Net cash flow from operating activities for Q1 2024 was -$64,845,661.88, an improvement from -$145,550,657.10 in Q1 2023[85] Research and Development - Total R&D investment amounted to ¥171,622,215.16, a decrease of 25.71%[27] - R&D investment as a percentage of operating revenue decreased by 42.90 percentage points to 106.21%[27] - Research and development expenses were $171.62 million in Q1 2024, down 25.7% from $231.02 million in Q1 2023[41] - Research and development expenses for Q1 2024 were CNY 173,059,632.30, down from CNY 233,112,801.12 in Q1 2023, a decrease of approximately 25.8%[82] - The company plans to continue focusing on R&D and market expansion strategies in the upcoming quarters[41] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,259,221,078.96, down 1.22% from the previous year[27] - Total assets as of Q1 2024 were $2.26 billion, a slight decrease from $2.29 billion in Q1 2023[52] - Total liabilities increased to CNY 1,164,943,634.68, up from CNY 1,073,907,031.98, representing a growth of approximately 8.1%[53] - The total owner's equity decreased to CNY 1,095,160,786.70 from CNY 1,214,195,857.31, reflecting a decline of about 9.8%[53] - The company's retained earnings showed a negative balance of CNY -2,351,443,995.19, worsening from CNY -2,232,408,924.58[53] - The total assets decreased slightly to CNY 2,259,221,078.96 from CNY 2,287,097,856.78, a decline of about 1.2%[64] - Total liabilities and shareholders' equity as of March 31, 2024, were CNY 2,260,104,421.38, a slight decrease from CNY 2,288,102,889.29 at the end of 2023[76] Operational Efficiency - Total operating costs decreased to $284.40 million in Q1 2024 from $323.39 million in Q1 2023, representing a reduction of 12.1%[41] - The company reported a decrease in sales expenses to $49.93 million in Q1 2024 from $41.04 million in Q1 2023[41] - Cash outflow for purchasing fixed assets and intangible assets in Q1 2024 was $43,235,271.99, a decrease of 53.1% from $92,098,312.72 in Q1 2023[85]

证券代码： 688177 证券简称： 百奥泰 公告编号：2024-026 百奥泰生物制药股份有限公司 自愿披露关于 TOFIDENCE（托珠单抗注射液）获 欧洲药品管理局人用药品委员会积极意见的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）的合作伙伴 Biogen International GmbH（以下简称"Biogen"）于近日收到了欧洲药品管理局 （以下简称"欧洲EMA"）的通知， TOFIDENCE（BAT1806，托珠单抗注射液） 获得欧洲EMA人用药品委员会（以下简称"CHMP"）积极意见。CHMP建议欧 盟委员会批准TOFIDENCE上市，用于治疗类风湿性关节炎、多关节型幼年特发 性关节炎、全身型幼年特发性关节炎和COVID-19。 现将相关情况公告如下： 一、 药品相关情况 药品名称：托珠单抗注射液 考虑到医药产品具有高科技、高风险、高附加值的特点，药品的前期研发 以及产品从研制、临床试验报批到投产的周期长，易受到技术、审批、政策等 多方面 ...

证券代码：688177 证券简称：百奥泰 公告编号：2024-025 百奥泰生物制药股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （一） 股东大会召开的时间：2024 年 4 月 18 日 （二） 股东大会召开的地点：广州市黄埔区永和经济开发区摇田河大街 155 号 E 栋 5K702 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 21 | | --- | --- | | 普通股股东人数 | 21 | | 2、出席会议的股东所持有的表决权数量 | 290,746,234 | | 普通股股东所持有表决权数量 | 290,746,234 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 70.2150 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 70.2150 | （四） ...

FANGDA PARTNERS http://www.fangdalaw.com 中国广东省广州市珠江新城 电子邮件 E-mail: email@fangdalaw.com 珠江东路 6 号 广州周大福金融中心 66 楼 电 话 Tel.: 86-20-3225-3888 邮政编码：510623 传 真 Fax: 86-20-3225-3899 66F, Guangzhou CTF Finance Centre, No.6 Zhujiang East Road, Zhujiang New Town Guangzhou, PRC 510623 上海市方达（广州）律师事务所 关于百奥泰生物制药股份有限公司 2023 年年度股东大会的法律意见书 致：百奥泰生物制药股份有限公司 上海市方达（广州）律师事务所（以下简称"本所"）是具有中华人民共和国 法律执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席百奥泰 生物制药股份有限公司（以下简称"公司"）2023 年年度股东大会（以下简称"本 次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集会议人员 的资格、表决程序和表决结果等有关事宜出具本法律意 ...

| 投资者关系 | □特定对象调研 □分析师会议 □媒体采访 □新闻发布会 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 活动类别 | √业绩说明会 □路演活动 □电话会议 | | | □现场参观 | | | | | | □其他： | | | | | | | | 时间 | 2024 年 4 月 日 15:00-17:00 | 15 | | | | | | | 地点 | 上证路演中心（网址：http://roadshow.sseinfo.com/） | | | | | | | | 接待人员 | 董事长、总经理：LI SHENGFENG（李胜峰）先生 董事、董事会秘书：鱼丹女士 | | | | | | | | | 财务总监：占先红女士 | | | | | | | | | 独立董事：HENRY WEI（魏亨利）先生 | | | | | | | | | 公司于 2024 4 月 15 日 在上证路演中心（网 | | 年 | 15:00-17:00 | | | | | | 址：http://roadshow.sseinfo.com/） ...

中国国际金融股份有限公司 关于百奥泰生物制药股份有限公司 首次公开发行股票并在科创板上市之持续督导保荐总结报告书 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意百奥泰生物 制药股份有限公司首次公开发行股票注册的批复》（证监许可[2020]92 号）核准并 经上海证券交易所同意，百奥泰生物制药股份有限公司（以下简称"百奥泰"或 "公司"或"上市公司"）获准公开发行人民币普通股 6,000 万股，募集资金总额 为人民币 196,560.00 万元。 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为公 司首次公开发行股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股 票上市规则》的相关规定，中金公司的持续督导期间为 2020 年 2 月 21 日至 2023 年 12 月 31 日。截至 2023 年 12 月 31 日，前述持续督导期限已届满。 截至 2023 年 12 月 31 日，公司首次公开发行的募集资金尚未使用完毕，中金 公司将对其募集资金使用情况继续履行持续督导义务。 中金公司根据《证券发行上市保荐业务管理办法》、《上海证券交易所上市公 司自律监管指引第 11 号 ...

中国国际金融股份有限公司 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）根据《证 券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》和《上海 证券交易所上市公司自律监管指引第 11 号——持续督导》等相关规定对百奥泰生 物制药股份有限公司（以下简称"百奥泰"、"公司"或"上市公司"）进行持续督 导，并出具本持续督导跟踪报告。 关于百奥泰生物制药股份有限公司 一、持续督导工作情况 2023 年度持续督导跟踪报告 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针 | 保荐机构已建立健全并有效执行了持续 | | | 对具体的持续督导工作制定相应的工作计划 | 督导制度，并制定了相应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开 | 保荐机构已与百奥泰签订《保荐协议》， | | | 始前，与上市公司或相关当事人签署持续督导 | 已明确双方在持续督导期间的权利和义 | | | 协议，明确双方在持续督导期间的权利义务， | 务，并已报上海证券交易所备案 | | | 并报上海证券交易 ...

中国国际金融股份有限公司 关于百奥泰生物制药股份有限公司 （六）现场检查手段： 1、对公司高级管理人员等有关人员进行访谈； 2023 年度持续督导工作现场检查报告 上海证券交易所： 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意百奥泰 生物制药股份有限公司首次公开发行股票注册的批复》（证监许可[2020]92号）注 册同意，百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"或"上 市公司"）公开发行人民币普通股6,000万股，发行价格为人民币32.76元/股。募集 资金总额为人民币196,560.00万元，扣除发行费用后，募集资金净额为人民币 187,619.98万元。 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为 百奥泰首次公开发行股票并持续督导的保荐机构，负责对百奥泰的持续督导工作。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所上市公司自律监管指引第11号——持续督导》《上海证券交易 所科创板上市公司自律监管指引第1号——规范运作》等有关法律、法规的规定， 本着审慎和勤勉尽责的原则，对公司2023年度的规范运作情况进行 ...

证券代码：688177 证券简称：百奥泰 百奥泰生物制药股份有限公司 2023年年度股东大会会议资料 2024 年 4 月 18 日 | 2023 年年度股东大会会议须知 | 2 | | | | --- | --- | --- | --- | | 年年度股东大会会议议程 2023 | 5 | | | | 2023 年年度股东大会议案 | 7 | | | | 议案一：关于公司 2023 | 年年度报告及摘要的议案 | 8 | | | 议案二：关于公司 2023 | 年度董事会工作报告的议案 | 9 | | | 议案三：关于公司 2023 | 年度监事会工作报告的议案 | 10 | | | 议案四：关于公司 2023 | 年度财务决算报告的议案 | 11 | | | 议案五：关于公司 2023 | 年度利润分配方案的议案 | 12 | | | 议案六：关于公司 2024 | 年度董事、监事和高级管理人员薪酬方案的议案 | 13 | | | 议案七：关于续聘 2024 | 年度会计师事务所的议案 | | 14 | | 议案八：关于向金融机构申请授信额度的议案 | | 18 | | | 议案九：关于提请股东大会授权董 ...

Investment Rating - The report maintains a "Buy" rating for the company [13][14]. Core Insights - The company achieved a revenue of 705 million yuan in 2023, representing a year-on-year growth of 54.86%. The net profit attributable to the parent company was a loss of 395 million yuan, which is a reduction of 17.87% compared to the previous year [13][14]. - The company is expected to enter a revenue realization phase in 2024 with the FDA approval of its products, including BAT1806, which is the first biosimilar to tocilizumab approved by the FDA [14]. - The company has a strong pipeline with ongoing research and development, including ADC drugs, and is positioned to capture market share in the biosimilar sector [14]. Financial Forecast - Revenue projections for 2024, 2025, and 2026 are 1.137 billion yuan, 1.581 billion yuan, and 2.212 billion yuan, respectively, with corresponding growth rates of 61.3%, 39.1%, and 40.0% [3][14]. - The net profit attributable to the parent company is forecasted to be -144 million yuan in 2024, 192 million yuan in 2025, and 639 million yuan in 2026, indicating a significant turnaround [3][14]. - The diluted earnings per share (EPS) are projected to be -0.35 yuan in 2024, 0.46 yuan in 2025, and 1.54 yuan in 2026 [3][14]. Market Position and Strategy - The company is one of the earliest players in the domestic market for biosimilars and has made significant strides in international markets, with two products already receiving FDA approval [14]. - The company’s strategy includes expanding its product offerings and enhancing its research capabilities, with a 24.70% increase in R&D investment in 2023 [14]. Conclusion - The report emphasizes the company's potential for growth driven by its strong product pipeline and market expansion strategies, supporting the "Buy" investment rating [13][14].